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prostate cancer needle biopsies to evaluate
biomarkers in non-surgically treated men
Naveen Kachroo1, Anne Y Warren2 and Vincent J Gnanapragasam1*Abstract
Background: Most biomarkers in prostate cancer have only been evaluated in surgical cohorts. The value of these
biomarkers in a different therapy context remains unclear. Our objective was to test a panel of surgical biomarkers
for prognostic value in men treated by external beam radiotherapy (EBRT) and primary androgen deprivation
therapy (PADT).
Methods: The Fluidigm® PCR array was used for multi-transcript profiling of laser microdissected tumours from archival
formalin-fixed diagnostic biopsies of patients treated by EBRT or PADT. Cases were matched for disease characteristics
and had known 5 year biochemical relapse outcomes (n = 60). Results were validated by immunohistochemistry in a
custom needle biopsy tissue microarray. Six biomarkers previously tested only in surgical cohorts were analysed (PTEN,
E-Cadherin, EGFR, EZH2, PSMA, MSMB). Transcript and protein expression was correlated with clinical outcome analysed
using Kruskal Wallis, Fisher’s test and Cox proportional hazard model.
Results: Altered expression of E-Cadherin (p = 0.008) was associated with early relapse after EBRT. In PADT treated men
however only altered MSMB transcript was prognostic for early relapse (p = 0.001). The remaining biomarkers however
did not demonstrate prognostic ability in either cohort. In a separate tissue array we validated altered E-Cadherin
protein as a predictor of early relapse after EBRT (n = 47) (HR 0.34, CI p = 0.02) but not in PADT treated men (n = 63).
Conclusion: We demonstrate proof of principle of multiple transcript profiling in archival diagnostic biopsies of
non-surgically treated men for biomarker discovery. We identify a role for E-Cadherin as a novel biomarker of early
relapse following EBRT.Background
Clinical prostate cancer can be effectively treated by dif-
ferent modalities including surgery and external beam
radiotherapy (EBRT) [1,2]. There is currently no way of
accurately predicting which therapy is best for an indi-
vidual patient who may be otherwise eligible for both
modalities [2,3]. Tissue biomarkers that can predict and
discriminate therapy outcome would therefore be an im-
portant and clinically useful tool. A critical issue with
prostate cancer biomarker research is the amount of tis-
sue available for analysis in non-surgically treated pa-
tients. As a result, the vast majority of biomarkers have
only been tested and validated in surgically treated men* Correspondence: vjg29@cam.ac.uk
1Translational Prostate Cancer Group, Hutchison/MRC research centre,
University of Cambridge, Hills Road, CB1 0XZ Cambridge, UK
Full list of author information is available at the end of the article
© 2014 Kachroo et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.[3]. For non-surgical therapies however the diagnostic nee-
dle biopsy is commonly the only tissue available to investi-
gate potential biomarkers. Standard immunohistochemistry
is not practical as a biomarker discovery platform because
of the limited tissue available and significant heterogeneity
in the biopsies. Moreover, only one candidate gene can usu-
ally be tested at a time.
Work in our group has developed methodology for
multi-gene transcript profiling from laser micro-dissected
formalin fixed paraffin embedded archival diagnostic nee-
dle biopsies [4-6]. In addition, we have recently undertaken
a detailed systematic analysis of the available literature on
tissue biomarkers within different therapy contexts [3].
This work has shown that there is a significant gap in the
evidence for the usefulness of surgical biomarkers in other
therapy contexts. In this study we bring together these two
strands of work and utilise transcript profiling of laserl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of a panel of biomarkers which have not been hitherto
tested in EBRT and/or primary androgen deprivation
treated (PADT) cohorts. Our principal aim is to test the
principle of simultaneously evaluating multiple surgically
derived biomarkers in biopsies of men treated by non-
surgical therapies and investigate if these will still retain
prognostic ability.
Methods
Clinical database and transcriptome bank
Patients treated by either external beam radiotherapy with
neo-adjuvant androgen deprivation (EBRT) or primary an-
drogen deprivation therapy (PADT) only and with 5 year
complete follow up data were identified from our hospital
registry based at Addenbrookes Hospital, Cambridge. The
study was conducted under specific ethical approval
(Cambridgeshire 2 Research Ethics Committee, ethics 09/
H0308/42). Men who had prolonged androgen deprivation
after EBRT (more than 6 months) were excluded from the
study. From these, men with and without early biochem-
ical relapse were identified and included into age and
tumour characteristic matched cohorts (n = 30 in each
treatment cohort, 15 relapse and non-relapse in each). To
achieve matching data was extracted from a cohort of
men identified from the hospital pathology/clinical registry
and we acquired relapsed cases first until we reached our
stated numbers. Then we acquired matched selected non-
relapse cases until we had the necessary cohort size. In
any instance where there was more than 1 suitable case
we selected the one with the closet match for the tumour
characteristics. Biochemical relapse was defined for each
treatment modality based on the EAU guidelines for pros-
tate cancer [7]. For EBRT this was a PSA value of 2 ng/ml
above the nadir. For PADT this was three consecutive
rises of PSA, 1 week apart, resulting in two 50% increases
over the nadir. The cohort size was derived based on a
priori sample size calculation with advice from in house
statisticians (University of Cambridge resource). Based on
our previous PCR based expression studies in formalin
fixed paraffin embedded tissue, we had established that at
least a 2 fold change in gene expression was necessary for
a significant difference. At a 90% power to detect a 2 fold
difference at the 1% level of significance, the sample size
required would be at least 20 in each treatment group (10
for each outcome). The present cohort size (30 in each
group) is therefore sufficient for this analysis particularly
as each variable would be considered independently.
The archived formalin fixed paraffin embedded (FFPE)
diagnostic needle biopsy tissue for each case was ac-
quired and all tumour areas in the tissue defined by a
uro-pathologist (AW) by marking on matching H&E
slides. All tumour areas were then laser capture micro-
dissected and RNA extracted using a FFPE optimisedprotocol as previously published [4-6]. cDNA was synthe-
sised (Transcriptor, Roche Diagnostics) and pre-amplified
using specific target amplification. Briefly, equal volumes
of 20× Taqman gene expression assay (see below for
primers) were combined in a pooled assay mix. For each
sample 1.25 μl cDNA (12.5 ng cDNA), 1.25 μl pooled assay
mix and 2.5 μl Taqman PreAmp Master Mix (Applied
Biosystems) was combined. These samples then under-
went a thermal cycle programme of 95°C for 10 minutes,
14 cycles of 15 seconds at 95°C and 4 minutes at 60°C.
The pre-amplified products were diluted to a 1:5 concen-
tration in TE buffer. As a quality control step primers for 3
housekeeping genes were also included (β actin, GAPDH,
RPL13) in the pre-amplification mix and tested by real
time PCR.
Biomarker panel
Candidate biomarkers were identified from a recent sys-
tematic review and had shown prognostic value in surgical
cohorts but had not been tested in other therapies: E
Cadherin, EGFR, EZH2, PTEN and MSMB [3]. These
markers are also exemplars of biological events that are crit-
ical to prostate cancer progression (metastasis, growth fac-
tor signalling, transcription factor, cell survival and inhibitor
of prostate cancer growth). We also included 3 highly pros-
tate and prostate cancer specific genes as expression con-
trols. The prostate marker PSMA which has shown promise
as a prognostic marker following surgery but has not been
tested in other treatment cohorts [8,9]. We also included
the androgen receptor (AR) which has not been tested in
EBRT therapy as well as the generic marker prostate cancer
antigen 3 (PCA3) [3,10,11]. All three were also selected as
they are very well described genes expressed in prostate tis-
sue and in prostate cancer. Taqman primers (Applied Bio-
systems) with the shortest amplicons lengths for these genes
were acquired for this study: E Cadherin: Hs01023894_m1,
EGFR: Hs01076078_m1, EZH2: Hs00544833_m1, PTEN:
Hs02621230_s1, MSMB: Hs00738230_m1, amp length
72 PSMA: Hs01020194_mH, AR: Hs00171172_m1, PCA3:
Hs01371939_g1, B-actin: Hs01060665_g1, GAPDH:
Hs03929097_s1, RPL13: Hs00742932_s1, amp length 81.
Fluidgm chip and quantitative real time PCR
The Fluidigm® 96.96 Dynamic Array integrated fluidic cir-
cuit chip was used to simultaneously profile the 9 gene
panel (including β actin) in the 60 tumours as well as 2 be-
nign prostate samples, 1 cancer line (PC3), 1 benign cell
line (PNT2), a RNA positive control (Clontech, CA, USA)
and a negative (water) control. Aliquots of each Gene Ex-
pression Assay were made up to a 10x concentration
[2.5 μl of 20X Taqman Assay (Applied Biosystems) and
2.5 μl 2X Loading Reagent (Fluidigm®)]. For each tumour
sample 2.5 μl Taqman Universal PCR Master Mix (Applied
Biosystems) was combined with 0.25 μl 20X GE Sample
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pre-amplified cDNA. Samples and assays were inputed
into the appropriate inlets and run on the integrated flu-
idic controller to load the chip. The chip was then run on
the Biomark Real Time PCR System using a cycling
programme of 10 minutes at 95°C, 40 cycles of 95°C for
15 seconds and 1 minute at 60°C. Data was analysed using
BioMark Gene Expression Data software to obtain Ct
values and delta Ct values (corrected for β actin). Results
shown are the mean of 3 assays which was replicated
twice. Results were analysed statistically using the Kruskal
Wallis test.
Needle biopsy tissue microarray (TMA)
A separate cohort of EBRT and PADT cases were identi-
fied and for which sufficient archival FFPE tissue from
diagnostic biopsies were available. Cases were again strati-
fied as early biochemical relapse or no-relapse and age/
tumour matched as described for the Fluidgm chip cohort
above. The biopsy cores to be sampled from the donor
blocks were marked on the corresponding Haematoxylin
and Eosin stained paraffin sections by a consultant uro-
histopathologist (AYW). These were selected by identify-
ing representative tumour containing cores and which
were used to ascribe the original tumour grade and extent
for each case. 2 mm cores were punched from a selected
area of the donor block using a disposable skin biopsy
punch. The 2 mm punches were melted at 60°C to remove
the excess wax and the donor cores embedded in the re-
cipient paraffin block, lined with a thin cellulose template
to act as a guide and to ensure that the cores from each
case remained separated from one another. Wherever pos-
sible the cores were orientated at 90° to its neighbour
which aided orientation during histological examination.
Core positions in the recipient paraffin block were noted
on a TMA map and a 2 mm pig kidney core was used as a
marker for orientation. Three micron sections were cut
and used for immunohistochemistry.
Immunohistochemistry and scoring
Mouse monoclonal Ki67 and E Cadherin (Leica Biosystems,
UK) antibodies have been previously validated [12,13]. The
Ki67 staining index was defined as the percentage of tumor
cells that displayed positive nuclear staining per high pow-
ered field. A 7.1% cut off was used as previously described
in radiotherapy immunohistochemistry studies with scores
averaged across 4 different fields per section [14]. Im-
munoreactivity signals for E Cadherin were assessed as
being absent or weak (0/+) and moderate or strong (++/+
++). Scoring was done by two independent observers
(AW&VG) blinded to the clinical detail and the scores
collated. Discordant scores were reviewed jointly and
rescored. Expression was compared between outcome
groups using Fishers exact test. Data for E Cadherin inEBRT treated men was further analysed together with
clinical variables in a Cox proportional hazards model for
EBRT therapy. p < 0.05 was considered as statistically
significant.
Results
Transcript expression of biomarker panel in biopsies
linked to clinical outcomes
The baseline clinico-pathological features of the matched
biochemical relapse and no-relapsed tumours included in
the Fluidigm® array are shown in Table 1. RNA from all
micro-dissected tumour samples were quality control
checked by real time PCR for a panel of house-keeping
genes using a previously reported method with good re-
sults (data not shown) [6,15]. In addition, all samples were
rechecked for housekeeping gene expression in the
Fluidigm® array chip (Figure 1). We first assessed expres-
sion of the AR and PCA3. AR expression was not associ-
ated with good or poor outcomes from either EBRT or
PADT treated cohorts (p = 0.49 and p = 0.75 respect-
ively) (Figure 2A). Similarly, we did not observe any cor-
relation between PCA3 expression and outcome from
EBRT or PADT in this study (Figure 2B). We next
assessed expression of the 5 surgical biomarker panel and
PSMA. PTEN expression has been strongly associated
with outcome in surgically treated men [16,17]. In this
study however PTEN expression was not associated with
good or poor outcomes from either EBRT or PADT treat-
ment (p = 0.54 and p = 0.34 respectively) (Figure 3A). We
similarly found that mRNA expression levels of EZH2,
EGFR and PSMA were also not statistically associated
with good or poor outcomes in EBRT or PADT treated
cohorts (Figure 3B-D). Reduced expression of MSMB has
been shown to be associated with a poor outcome from
surgery but has not been tested in EBRT cohorts. In this
study MSMB had no prognostic value in EBRT treated
men (p = 0.93) (Figure 4A). We did however find that
MSMB expression was lower in men who had a poorer
outcome from PADT. Of note, although the PADT groups
in this study did not show statistical differences in the
clinico-pathological characteristics there were more high
grade, stage and metastasis cases in the relapse group
(Table 1). Thus, a larger sample size may not detect this
difference and this warrants further validation.
Loss of E Cadherin has been shown to be a strong pre-
dictor of surgical outcomes in a number of studies
[18,19]. In this study reduced E Cadherin mRNA was
significantly associated with a poorer outcome in EBRT
but not PADT treated cohorts (p = 0.008 and p = 0.26
respectively) (Figure 4B).
Immuno-histochemical validation of novel targets
To further test the protein validity of our results with E
Cadherin, we assembled a TMA of archival needle
Table 1 Baseline demographic data on disease characteristics of the cohort used in the transcript expression analysis
stratified by early biochemical relapse or no-relapse (EBRT - external beam radiotherapy, PADT - primary androgen
deprivation therapy)
PADT No relapse PADT relapse p value EBRT No relapse EBRT relapse p value
Sample size n = 15 n = 15 n = 15 n = 15
Mean age 74 (57-78) 69 (60-78) p = 0.09 NS 65 (58-71) 67 (52-77) p = 0.26 NS
Mean presenting PSA (ng/ml) 23.9 (2.5-90.3) 25 (5.2-251) p = 0.36 NS 15.5 (4.1-27.9) 23.9 (3.6-107) p = 0.25 NS
Clinical stage p = 0.06 NS p = 0.89 NS
T1 2 0 2 4
T2 9 7 8 5
T3 4 7 5 6
T4 0 1 0 0
Principle Gleason grade p = 0.17 NS p = 0.78 NS
Gleason 3 7 4 12 11
Gleason 4 6 6 2 4
Gleason 5 2 5 1 0
Gleason grade sum p = 0.25 NS p = 0.93 NS
6 3 1 8 7
7 7 4 5 7
8 0 5 0 0
9 4 4 1 1
10 1 1 1 0
Metastasis p = 0.2 NS p = 1.00 NS
M0 13 9 15 15
M1 2 6 0 0
Figure 1 Expression of housekeeping genes (β actin showed here) in laser micro-dissected individual tumours from archival formalin
fixed paraffin embedded diagnostic biopsies from men treated by A. External beam radiotherapy (EBRT) B. Primary androgen
deprivation therapy (PADT).
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Figure 2 Pooled transcript expression corrected to β actin micro-dissected archival FFPE diagnostic biopsies of men treated by EBRT
or PADT and stratified by early biochemical relapse or no-relapse. A. Expression of AR B. Expression of PCA3.
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identified from the clinical database and with known
5 year biochemical relapse outcomes. Tumours were
again matched for grade, stage and presenting PSA. To
test the robustness of this TMA we first interrogated for
protein expression of the global prognostic marker Ki67.
In both EBRT and PADT TMA, Ki67 was significantly
over-expressed in the early relapse group compared to
the non-relapse cohort using previously described scor-
ing criteria (p = 0.0006 and p = 0.0004 respectively)
(Figure 5A&B). These results are consistent with the
published literature [20-22]. We next tested protein ex-
pression of E Cadherin in both groups using validated
antibodies. In the EBRT cohort reduced E Cadherin pro-
tein was again significantly associated with early devel-
opment of biochemical recurrence (p = 0.04) (Table 2)
(Figure 5C&D). We further analysed the results in a
Cox proportional hazards model including the clinical
variables of presenting PSA, Gleason sum score and
clinical stage. These variables were unsurprisingly not
associated with outcomes as cases for this analysis had
been matched for tumour characteristics. In this model
however loss of E Cadherin was independently associ-
ated with an increase likelihood of early treatment fail-
ure (HR 0.34 [0.1-0.8] p = 0.02) (Table 3). In contrast E
Cadherin protein expression was not associated with
clinical outcome in PADT treated men. These data lendsupport to our initial observation at the transcript level
of the prognostic value of E Cadherin expression for
EBRT treated men but its lack of value in men treated
by PADT.
Discussion
The use of FFPE tissue for prognostic transcript profiling
in prostate cancer is not new [23,24]. Indeed, prognostic
gene panels are about to enter mainstream commercial
use for predicting prostate cancer therapy outcome
[25,26]. With reducing costs the era of massive parallel
sequencing will soon be feasible for clinical use. How-
ever such platforms generally require good quality tissue
input material and do not work so well on archival and
FFPE tissue. PCR based assays however have been opti-
mised to address this and new commercial tests have
emerged that work well on prostate FFPE tissue [25].
Here we have sought to use PCR based FFPE transcript
profiling to specifically test biomarkers in different ther-
apy contexts and to our knowledge this approach is
novel. Furthermore, our use of laser microdissected tu-
mours dramatically increases the specificity and accuracy
of profiling tumour cells without benign and stromal
contamination [4,27]. Using an FFPE optimised multi-
plex PCR platform we have been able to simultaneously
analyse a number of biomarkers in well characterised
treatment specific good and poor outcome cohorts.
Figure 3 Pooled transcript expression corrected to β actin in micro-dissected archival FFPE diagnostic biopsies of men treated by EBRT
or PADT and stratified by early biochemical relapse or no-relapse. A. Expression of PTEN B. Expression of EZH2. C. Expression of EGFR.
D. Expression of PSMA.
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loss of E Cadherin at the mRNA level is associated with
a poorer outcome from EBRT but not in PADT treated
men. We were further able to validate the results at the
protein level in a custom made needle biopsy TMA. To
our knowledge this is the first study to report on aber-
rant E Cadherin as a biomarker in EBRT for primary
prostate cancer. One study in 2006 had reported that E
Cadherin was a useful biomarker for patients who had
subsequent salvage EBRT after RRP [28]. In this study
however expression was profiled in the resected surgicalsample and not the initial diagnostic biopsies. This is also
the first study to explore E Cadherin in PADT treated men
where no association was found with outcome at either the
mRNA or protein level. The mechanistic rationale for the
differential predictive ability of E Cadherin between EBRT
and PADT in this study is intriguing. Recent studies have
shown that EMT is associated with radioresistance in pros-
tate cancer cells. Chang et al developed 3 radio resistant
prostate cancer cell lines and demonstrated enhanced
EMT phenotypes compared to controls [29]. Zhou et al
have also previously shown that radiation therapy enhances
Figure 4 Pooled transcript expression corrected to β actin micro-dissected archival FFPE diagnostic biopsies of men treated by EBRT
or PADT and stratified by early biochemical relapse or no-relapse. A. Expression of MSMB B. Expression of E Cadherin (*p = 0.02, **p < 0.01).
Figure 5 Immunohistochemistry in diagnostic biopsies from EBRT treated men. A. Low Ki67 expression B. High Ki67 expression. C. Low E
Cadherin expression. D. High E Cadherin expression (X40 magnification for all images).
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Table 2 Immunohistochemistry data on protein
expression of Ki67 and E Cadherin stratified by early
biochemical relapse or no-relapse
EBRT treatment No relapse Relapse
Ki67 (n = 54) Low 26 4
High 9 15 p = 0.0004
E Cadherin (n = 47) 0/+ 7 8
++/+++ 25 7 p = 0.04
PADT treatment No relapse Relapse
Ki67 (n = 53) 0/+ 20 5 p = 0.0003
++/+++ 8 20
E Cadherin (n = 63) 0/+ 5 4
++/+++ 20 34 p = 0.4
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[30]. Our work is the first to demonstrate the potential
clinical association with EMT and radiotherapy outcome
and lends support to these in vitro observations. If cancer
cells have already acquired the EMT phenotype before ra-
diation then it is more likely that this will promote micro-
metastasis, radioresistance and early treatment failure. Loss
of MSMB mRNA expression was however associated with
early biochemical relapse in PADT treated men and is con-
sistent with one older study has also previously shown that
loss of expression was a predictor of a poor outcome in a
mixed treatment group including men treated by primary
androgen deprivation [31]. A number of other well known
surgical biomarkers did not appear to have prognostic util-
ity in different therapy contexts in our cohort. Work by
Mucci and others have also previously shown this lack of
transferability of biomarkers across therapies [32,33]. We
fully acknowledge that our discovery sample size is small
(though matched and enriched for clinical outcomes) and
we may have missed significant positive findings because
of this. We therefore do not claim that our study rules out
a role for the negative biomarkers tested.
The results of this study do raise important issues
about biomarker discovery and use in non-surgically
treated men. Prognostic ability in one context should
not be extrapolated to other treatments without robustTable 3 Cox proportional hazards model incorporating
clinical variables and E Cadherin immune-staining scores
in diagnostic biopsies as prognostic factors for early
biochemical relapse for the external beam radiotherapy
treated cohort
Hazard ratio 95% Confidence interval p value
Presenting PSA 1.14 0.41-3.20 0.79
Clinical stage 0.79 0.21-3.01 0.73
Gleason sum 2.31 0.76-7.03 0.13
E Cadherin 0.34 0.13-0.89 0.02validation. This is a critical distinction if biomarkers are to
be used to help therapy selection for patients and to guide
future studies. The use of biomarkers in this context
therefore must consider the treatment effect on cells and
the mechanism of therapy resistance. Of note we had also
found other surgical biomarkers in our previous review
which had not been tested in EBRT or PADT cohorts [3].
Based on the encouraging results from this study we now
intend to test these other markers further and within a ra-
tionale approach for therapy response and resistance. This
work has shown the feasibility of testing multiple bio-
markers in non-surgical cohorts. Clearly, this provides a
very useful discovery platform but emergent markers need
validation in independent and large cohorts. Optimised
discovery methods however mean that such validation can
be done using a targeted approach and with less resource
intensive methods such as protein immunohistochemistry.
Indeed we propose to further validate our current findings
in larger cohorts from other collaborator centres and this
work is underway. In the future testing fewer more rele-
vant markers but in large datasets is the best route to rap-
idly developing clinically useful prognostic tools [34,35].
There are a number of inherent limitations in this re-
port. Our sample size (discovery and validation cohorts)
although matched for clinic-pathological features, is rela-
tively modest. The use of archival formalin fixed tissue is
subject to mRNA degradation but we have applied opti-
mised methodology for extraction as well as the use of
short amplicons in PCR and well described quality con-
trol tests [4,16]. We were not able to cross validate PCR
and immunohistochemistry expression in the same sam-
ple as there was very limited amounts of tissue. However
we were able to demonstrate the same results in separate
cohorts which we believe is a strength of the study. We
also acknowledge that needle biopsies may often under-
estimate the true disease burden in men treated by non-
surgical therapy. However as previously discussed it is
the only tissue that is ever available in EBRT and PADT
treated men. Of note, the increasing use of template
perineal and MRI guided prostate biopsies has already
resulted in the real possibility of very accurate characterisa-
tion of the tumour burden from diagnostic needle biopsies
alone and in men who will never have the prostate removed
[36,37]. The ability to perform transcript profiling in this
context will become increasingly more relevant in identify-
ing clinically useful biomarkers in non-surgical therapies.
Finally, we were specifically interested in early biochemical
relapse as a clinical outcome in this study. We are planning
to follow the association of expression with metastasis and
clinical progression outcome as the cohort matures.
Conclusion
In summary we have applied multi-transcript profiling
in well characterised cohorts to assess tissue biomarkers
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We show feasibility for simultaneous multiple biomarker
testing in enriched tumour tissue from the original diag-
nostic needle biopsies as a platform for biomarker studies.
This method would be particular useful to discover novel
biomarkers specific to EBRT and other non-surgical ther-
apies with the aim of targeted and rational validation in
larger cohorts. In this context we demonstrate preliminary
evidence for E Cadherin as a novel biomarker of EBRT
outcome which warrants further investigation in larger
multi-centre studies. Other biomarkers derived from sur-
gical studies may not however have utility in a different
therapy context suggesting that robust testing in appropri-
ate cohorts is needed before inclusion in global prognostic
models.
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